PPT-Management of HER2 Over-Expressed Breast Cancer in the Adjuvant, Neoadjuvant, and Metastatic

Management of HER2 OverExpressed Breast Cancer in the Adjuvant Neoadjuvant and Metastatic settings Christy A Russell MD Keck School of Medicine University of Southern California Metastatic Breast Cancer. Joyce O'Shaughnessy, MD. Kimberly Blackwell, MD. Hope . Rugo. , MD. Reminder: feedback is appreciated. You will be prompted at the end for your feedback.. Updates on Chemotherapy and Other Novel Agents. Triple Negative Breast Cancer. Steven J. Isakoff, MD, PhD. Dana-Farber . Harvard Cancer . Center/ Massachusetts General Hospital Cancer . Center. August 19, 2017. sisakoff@partners.org. 46 year-old premenopausal woman . Jennifer M. Matro, MD. Rena Rowan Breast Center. Abramson Cancer Center. University of Pennsylvania. Overview. What is metastatic breast . c. ancer (MBC)?. Who is at risk?. Subtypes of Breast Cancer. ASCO-CAP Recommendations For HER2 Testing in Breast Cancer. Criteria For Reporting HER2 Test Results . as Positive. Criteria for Reporting HER2 Test Results . as Negative. Criteria for Reporting Equivocal Results . Dr. . Khaled Abulkhair, PhD. Medical Oncology SCE, Royal College, UK. Ass. Professor of Clinical Oncology. Mansoura University, Egypt. A long Road Searching for optimum Neo-Adjuvant Therapy in Her -2 Positive Breast Cancer. Antonella Brunello . Kwok-Leung Cheung. Disclosure. No . conflict. of . interests. Learning objectives. To . discuss the pros and cons of adjuvant chemotherapy for breast cancer in the elderly. To . Triple-Negative Breast Cancer. Jamie Carroll, APRN, MSN, CNP. Hope S . Rugo. , MD. . Disclosures for . Ms. Carroll. No financial interests or affiliations to disclose. Disclosures for Dr . Rugo. Contracted Research. Heather M. Gage, MD, Avanti . Rangnekar. , Robert E. Heidel, . PhD. , Timothy Panella, MD, John Bell, MD, and Amila Orucevic, MD, . PhD. The Graduate School of Medicine. The Department of Pathology. Introduction. in Development for . Breast Cancer. Sara A. Hurvitz, MD, FACP. Professor of Medicine. David Geffen School of Medicine, UCLA. Los Angeles, CA. William J. Gradishar, MD, FASCO, FACP. Betsy Bramsen Professor of Breast Oncology & Professor of Medicine. Sara A. Hurvitz, MD, FACP. Professor of Medicine. David Geffen School of Medicine, UCLA. Los Angeles, CA. William J. Gradishar, MD, FASCO, FACP. Betsy Bramsen Professor . of Breast Oncology . & Professor of Medicine. Anne Sofie Brems-Eskildsen. Department of Oncology, University Hospital of Aarhus. Guidelines in . Oncology . for ILC follows IDC. ASCO . G. uidelines . for early breast cancer (not mentioned). St. . . therapy. . is. to be . used. in post-. menopausal. . breast. . cancer. woman. Antonino . Grassadonia. Università «G. D’Annunzio» – Chieti-Pescara. Neoadjuvant . Systemic Therapy of . Primary . . Breast Cancer | . Epidemiology- Australia. Australian Institute of Health and Welfare 2014. ACIM (Australian Cancer Incidence and Mortality) Books. Canberra. AIHW. Overall is the third leading cause of cancer. Jo Anne Zujewski, M.D.. June 2019. Thimphu. , Bhutan. Define the breast cancer. Is the cancer operable?. Stage 1: systemic therapy after surgery (and radiation if breast conservation). Stage 2: systemic therapy before or after therapy.